NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE

3 May 2024

2024 Annual General Meeting - Results of Meeting

Next Science Limited (ASX:NXS) ("Next Science" or "the Company") advises that the results of the 2024 Annual General Meeting held today are set out in the attached report. All resolutions were passed by the requisite majority and determined by way of a poll.

These results are provided in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act* 2001 (Cth).

Approved and authorised for release by CEO & Managing Director

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

NEXT SCIENCE LIMITED



RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING Friday, 3 May, 2024

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Direct vote (as at proxy close):		Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	For	Against	Abstain **	Result
1	REMUNERATION REPORT	N	78,273,277 56.70%	0	315,988 0.23%	66,634	59,205,844 42.89%	261,501 0.19%	137,911,565 99.72%	394,038 0.28%	85,634	Carried
2	ELECTION OF GRANT HUMMEL	NA	78,273,277 54.28%	0.00%	325,988 0.23%	63,059	65,573,966 45.47%	40,588 0.03%	144,422,224 99.97%	40,588 0.03%	469,753	Carried
3	ELECTION OF KATHERINE OSTIN	NA	78,273,277 54.29%	0.00%	325,988 0.23%	109,784	65,534,335 45.46%	33,494 0.02%	144,770,287 99.96%	52,494 0.04%	109,784	Carried
4	APPROVAL TO ISSUE SECURITIES UNDER THE NEXT SCIENCE EQUITY PLAN RULES	NA	78,266,916 56.71%	6,361 0.00%	315,988 0.23%	385,954	59,106,851 42.83%	313,165 0.23%	137,938,748 99.76%	338,526 0.24%	385,954	Carried
5	APPROVAL TO ISSUE LTIP OPTIONS AND RIGHTS TO THE MANAGING DIRECTOR & CEO	NA	78,259,216 54.33%	14,061 0.01%	315,988 0.22%	33,037	65,080,046 45.18%	374,530 0.26%	144,256,549 99.69%	442,979 0.31%	33,037	Carried
6	APPROVAL TO ISSUE SIGN-ON RIGHTS TO THE MANAGING DIRECTOR & CEO	NA	78,266,916 54.33%	6,361 0.00%	315,988 0.22%	26,293	65,080,046 45.18%	381,274 0.26%	144,299,637 99.72%	406,635 0.28%	26,293	Carried
7	RENEW PROPORTIONAL TAKEOVER PROVISIONS	NA	78,265,577 54.25%	7,700 0.01%	315,988 0.22%	15,798	65,619,938 45.49%	51,877 0.04%	144,857,190 99.96%	59,577 0.04%	15,798	Carried

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item